<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305587</url>
  </required_header>
  <id_info>
    <org_study_id>C3991002</org_study_id>
    <nct_id>NCT04305587</nct_id>
  </id_info>
  <brief_title>Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind (investigator- and
      participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with
      Type 2 diabetes on metformin (Parts A and C). The study may also enroll non-diabetic
      participants with obesity (Part B). Study participants will receive an investigational
      product or placebo every day for up to 28 days (Part A) or up to 42 days (Part B, optional;
      Part C, optional).

      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
      of multiple oral doses of PF-07081532 in participants with inadequately controlled T2DM on
      metformin and optionally in non-diabetic obese participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Anticipated">January 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind (investigator- and participant-blind), sponsor-open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Treatment-Related Adverse Events</measure>
    <time_frame>Baseline up to a minimum of 28 days after last administration of investigational product.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities</measure>
    <time_frame>From Baseline to 7-14 days following last dose administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinically Significant Change from Baseline in Vital Signs</measure>
    <time_frame>From Baseline to 7-14 days following last dose administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormal Electrocardiogram</measure>
    <time_frame>From Baseline to 7-14 days following last dose administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC24: Area under the Curve from time zero to 24 hours post dose.</measure>
    <time_frame>Part A: 0-24 hours post-dose on selected study days from day 1 to day 28. Parts B/C (if conducted): 0-24 hours post-dose on selected study days from day 1 to day 42.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration</measure>
    <time_frame>Part A: selected study days from day 1 to day 28. Parts B/C (if conducted): selected study days from day 1 to day 42.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach Maximum Observed Plasma Concentration</measure>
    <time_frame>Part A: selected study days from day 1 to day 28. Parts B/C (if conducted): selected study days from day 1 to day 42.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t 1/2: Time measured for the plasma concentration to decrease by one-half.</measure>
    <time_frame>Part A: Day 28 0-72 hours post-dose. Parts B/C (if conducted): also day 42 0-72 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae24: Cumulative Amount of Drug Recovered Unchanged in Urine</measure>
    <time_frame>Part A: Day 28 (0-24 hrs). Part C (if conducted): Day 42 (0-24 hrs).</time_frame>
    <description>Ae24 is the cumulative amount of drug recovered unchanged in urine over 24 hours. Cumulative amount is calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram [g]/1.020) where 1.020 g/mL is the approximate specific gravity of urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae24%: Percentage of dose recovered in urine as unchanged drug</measure>
    <time_frame>Part A: Day 28 (0-24 hrs). Part C (if conducted): Day 42 (0-24 hrs).</time_frame>
    <description>Calculated as 100 x Ae24 divided by the dose administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr: Renal Clearance</measure>
    <time_frame>Part A: Day 28 (0-24 hrs). Part C (if conducted): Day 42 (0-24 hrs).</time_frame>
    <description>Renal clearance is calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae24) divided by area under the plasma concentration time curve from time zero to end of dosing interval (AUC24), where dosing interval is 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Active Obesity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Obesity</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active T2DM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parts A and C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo T2DM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Parts A and C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07081532</intervention_name>
    <description>Investigational Drug once daily for up to 42 days; multiple ascending dose design.</description>
    <arm_group_label>Active Obesity</arm_group_label>
    <arm_group_label>Active T2DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for up to 42 days.</description>
    <arm_group_label>Placebo Obesity</arm_group_label>
    <arm_group_label>Placebo T2DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.</description>
    <arm_group_label>Active Obesity</arm_group_label>
    <arm_group_label>Placebo Obesity</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria for participants enrolling with T2DM:

          -  Type 2 Diabetes treated with a stable dose of metformin at least 500 mg per day for at
             least 2 months prior to screening visit and use of no other medications for glycemic
             control.

          -  HbA1c value between 7.0% and 10.5%, inclusive.

        Key Exclusion Criterion for participants enrolling with T2DM:

        -Type 1 Diabetes or secondary forms of diabetes.

        Key Inclusion Criterion for participants enrolling with obesity:

        -Obese (as indicated by screening BMI) non-diabetic adults.

        Key Exclusion Criterion for participants enrolling with obesity:

        --Type 1 or Type 2 Diabetes or secondary forms of diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qps-Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3991002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

